

H₂Mab-77 is a Sensitive and Specific Anti-HER2 Monoclonal Antibody Against Breast Cancer

Shunsuke Itai^{1,2,*}, Yuki Fujii^{3,*}, Mika K. Kaneko¹, Shinji Yamada¹, Takuro Nakamura¹, Miyuki Yanaka¹, Noriko Saidoh¹, Yao-Wen Chang¹, Saori Handa¹, Maki Takahashi⁴, Hiro Yoshi Suzuki⁴, Hiroyuki Harada², and Yukinari Kato^{1,3,5}

Human epidermal growth factor receptor 2 (HER2) plays a critical role in the progression of breast cancers, and HER2 overexpression is associated with poor clinical outcomes. Trastuzumab is an anti-HER2 humanized antibody that leads to significant survival benefits in patients with HER2-positive metastatic breast cancers. In this study, we developed novel anti-HER2 monoclonal antibodies (mAbs) and characterized their efficacy in flow cytometry, Western blot, and immunohistochemical analyses. Initially, we expressed the full length or ectodomain of HER2 in LN229 glioblastoma cells and then immunized mice with ectodomain of HER2 or LN229/HER2, and performed the first screening by enzyme-linked immunosorbent assays using ectodomain of HER2. Subsequently, we selected mAbs according to their efficacy in flow cytometry (second screening), Western blot (third screening), and immunohistochemical analyses (fourth screening). Among 100 mAb clones, only three mAbs reacted with HER2 in Western blot, and clone H₂Mab-77 (IgG₁, kappa) was selected. Finally, immunohistochemical analyses with H₂Mab-77 showed sensitive and specific reactions against breast cancer cells, warranting the use of H₂Mab-77 to detect HER2 in pathological analyses of breast cancers.

Keywords: HER2, monoclonal antibody, immunohistochemistry, breast cancer

Introduction

HUMAN EPIDERMAL GROWTH FACTOR RECEPTOR 2 (HER2) plays an important role in the progression of breast cancers, and its overexpression was reported in >20% of patients with breast cancer.^(1,2) HER2 overexpression is associated with poor clinical outcomes, and the monoclonal antibodies (mAbs) trastuzumab⁽³⁾ and pertuzumab,⁽⁴⁾ the tyrosine kinase inhibitor lapatinib,⁽⁵⁾ and the antibody–drug conjugate (ADC) of trastuzumab and the maytansinoid microtubule assembly inhibitor trastuzumab emtansine⁽⁶⁾ have been approved for the treatment of HER2-positive breast cancers. Treatment with trastuzumab demonstrated significant survival benefits for patients with HER2-positive metastatic breast cancers.⁽⁷⁾ Furthermore, dual blockade of HER2 with the combination of pertuzumab and trastuzumab, as well as chemotherapy, led to significant improvements in overall survival compared with trastuzumab plus chemotherapy.⁽⁸⁾

Previously, we developed an original technology for the production of cancer-specific monoclonal antibodies (Cas-

Mabs) and anti-glycopeptide mAbs (GpMabs) against membrane proteins.⁽⁹⁾ We also developed sensitive and specific mAbs against several other membrane proteins using the same technology.^(10–13) In this study, we developed anti-HER2 mAbs for use in flow cytometry, Western blot, and immunohistochemical analyses.

Materials and Methods

Cell lines

LN229, A431, SK-BR-3, Chinese hamster ovary (CHO)-K1, HEK-293T, Met-5A, and P3U1 cell lines were obtained from the American Type Culture Collection (ATCC, Manassas, VA). LN229/HER2 and CHO/HER2 were produced by transfecting pCAG/PA-HER2-RAP-MAP⁽¹⁴⁾ into LN229 and CHO-K1 cells using Neon transfection system (Thermo Fisher Scientific, Inc., Waltham, MA) and Lipofectamine LTX (Thermo Fisher Scientific, Inc.), respectively. A few days after transfection, PA tag-positive

¹Department of Antibody Drug Development, Tohoku University Graduate School of Medicine, Aoba-ku, Sendai, Miyagi, Japan.

²Department of Oral and Maxillofacial Surgery, Graduate School of Medical and Dental Sciences, Tokyo Medical and Dental University, Yushima, Bunkyo-ku, Tokyo, Japan.

³Department of Regional Innovation, Tohoku University Graduate School of Medicine, Aoba-ku, Sendai, Miyagi, Japan.

⁴Department of Pathology and Laboratory Medicine, Sendai Medical Center, Miyagino, Miyagino-ku, Sendai, Miyagi, Japan.

⁵New Industry Creation Hatchery Center, Tohoku University, Aoba-ku, Sendai, Miyagi, Japan.

*Both authors contributed equally to this work.

cells⁽¹⁵⁾ were sorted using a cell sorter (SH800; Sony Corp., Tokyo, Japan).

CHO-K1, CHO/HER2, and P3U1 cell lines were cultured in RPMI 1640 medium (Nacalai Tesque, Inc., Kyoto, Japan), and LN229, LN229/HER2ec, LN229/HER2, A431, SK-BR-3, HEK-293T, and Met-5A cell lines were cultured in Dulbecco's modified Eagle's medium (Nacalai Tesque, Inc.), supplemented with 10% heat-inactivated fetal bovine serum (Thermo Fisher Scientific, Inc.), 100 units/mL of penicillin, 100 µg/mL of streptomycin, and 25 µg/mL of amphotericin B (Nacalai Tesque, Inc.) at 37°C in a humidified atmosphere containing 5% CO₂ and 95% air.

Animals

Female 4-week-old BALB/c mice were purchased from CLEA Japan (Tokyo, Japan). Animals were housed under pathogen-free conditions. The Animal Care and Use Committee of Tohoku University approved all of the animal experiments described herein.

Tissues

One breast cancer patient who underwent surgery at Sendai Medical Center was recruited for examinations, and the ethics committee of Sendai Medical Center approved this study. Normal and cancer tissues were purchased from BioChain Institute, Inc. (Newark, CA) and US Biomax, Inc. (Rockville, MD), respectively.

Hybridoma production

The ectodomain of HER2 with N-terminal PA tag⁽¹⁵⁾ and C-terminal RAP tag⁽¹⁶⁾ -MAP tag⁽¹⁴⁾ (HER2ec) was purified from supernatant of LN229/HER2ec using anti-MAP tag as described previously.⁽¹⁴⁾ BALB/c mice were immunized using intraperitoneal (i.p.) injections of LN229/HER2 cells or 100 µg of HER2ec together with Imject Alum (Thermo Fisher Scientific, Inc.). After several additional immunizations, a booster injection of LN229/HER2 cells or 100 µg of HER2ec was intraperitoneally administered 2 days before harvesting spleen cells. Spleen cells were then fused with P3U1 cells using PEG1500 (Roche Diagnostics, Indianapolis, IN) or GenomONE-CF (Ishihara Sangyo Kaisha, Ltd., Osaka, Japan).

The resulting hybridomas were grown in RPMI medium supplemented with hypoxanthine, aminopterin, and thymidine selection medium supplement (Thermo Fisher Scientific, Inc.). Culture supernatants were screened using enzyme-linked immunosorbent assay (ELISA) with HER2ec, and mAbs were screened using flow cytometry (second screening), Western blot (third screening), and immunohistochemical analyses (fourth screening). MAbs were purified from supernatants of hybridomas cultured in Hybridoma-SFM medium (Thermo Fisher Scientific, Inc.) using Protein G Sepharose 4 Fast Flow (GE Healthcare UK Ltd, Buckinghamshire, England).

Flow cytometry

Cells were harvested by brief exposure to 0.25% trypsin/1-mM ethylenediaminetetraacetic acid (EDTA) (Nacalai Tesque, Inc.). After washing with 0.1% bovine serum albumin (BSA)/phosphate-buffered saline, the cells were treated with 1 µg/mL of anti-HER2 (clone H₂Mab-77) for 30 minutes at 4°C and then with Oregon green-conjugated anti-mouse

IgG (1:1000 diluted; Thermo Fisher Scientific, Inc.). Fluorescence data were collected using EC800 or SA3800 Cell Analyzers (Sony Corp.).

Western blot analysis

Cell lysates (10 µg) were boiled in the sodium dodecyl sulfate (SDS) sample buffer (Nacalai Tesque, Inc.) and proteins were then electrophoresed on 5%–20% polyacrylamide gels (Wako Pure Chemical Industries Ltd., Osaka, Japan), and were transferred onto polyvinylidene difluoride (PVDF) membranes (Merck KGaA, Darmstadt, Germany). After blocking with 4% skim milk (Nacalai Tesque, Inc.), membranes were incubated with 1 µg/mL of primary antibodies, such as anti-HER2 (clone H₂Mab-77) and anti-β-actin (clone AC-15; Sigma-Aldrich Corp., St. Louis, MO), and then with peroxidase-conjugated anti-mouse IgG (1:1000 diluted; Agilent Technologies, Inc., Santa Clara, CA), and were finally developed using ImmunoStar LD (Wako Pure Chemical Industries Ltd.) using a Sayaca-Imager (DRC Co. Ltd., Tokyo, Japan).

Determination of the binding affinity using flow cytometry

A431 and SK-BR-3 (2×10^5 cells) were suspended in 100 µL of serially diluted mAbs (0.6 ng/mL–10 µg/mL), and Alexa Fluor 488-conjugated anti-mouse IgG (1:1000; Cell Signaling Technology, Inc., Danvers, MA) was then added. Fluorescence data were collected using a cell analyzer (EC800; Sony Corp.). The dissociation constants (K_D) were calculated by fitting the binding isotherms using the built-in one-site binding models in GraphPad PRISM 6 (GraphPad software, Inc., La Jolla, CA).

Immunohistochemical analyses

Histologic sections of 4-µm thickness were deparaffinized in xylene and then rehydrated and autoclaved in citrate buffer (pH 6.0; Agilent Technologies, Inc.) for 20 minutes. Sections were then incubated with 1 µg/mL of primary mAbs for 1 hour at room temperature and then treated using an Envision+ kit (Agilent Technologies, Inc.) for 30 minutes. Color was developed using 3,3-diaminobenzidine tetrahydrochloride (Agilent Technologies, Inc.) for 2 minutes, and sections were then counterstained with hematoxylin (Wako Pure Chemical Industries Ltd.). The intensity of staining was evaluated as 0, 1+, 2+, and 3+.

Results

Production of anti-HER2 mAbs

Herein, we immunized mice with LN229/HER2 or purified recombinant HER2ec from culture supernatants of LN229/HER2ec cells. A booster i.p. injection of LN229/HER2 or HER2ec was also administered and culture supernatants were then screened for binding to purified HER2ec using ELISA. As a second screen, we used flow cytometry analyses to assess reactions with LN229 and LN229/HER2 cells. Because LN229 cells express endogenous HER2, a stronger reaction against LN229/HER2 was necessary.

A total of 29 clones were generated from immunizations with LN229/HER2, and 71 were generated from immunizations with purified HER2ec. Among 100 clones, 96




FIG. 1. Characterization of H₂Mab-77. (**A**, **B**) Flow cytometry with H₂Mab-77; cells were treated with 1 μg/mL of H₂Mab-77 followed by Oregon green-conjugated anti-mouse IgG; black line, negative control. (**C**) Western blot using H₂Mab-77; cell lysates (10 μg) were electrophoresed and proteins were transferred onto PVDF membranes. After blocking, membranes were incubated with 1 μg/mL of H₂Mab-77 or anti-β-actin (AC-15), and then incubated with peroxidase-conjugated anti-mouse IgG. (**D**) Binding affinity of H₂Mab-77 was determined using flow cytometry. A431 and SK-BR-3 cells were suspended in 100 μL of serially diluted H₂Mab-77 (0.6 ng/mL–10 μg/mL) and secondary anti-mouse IgG was then added. Fluorescence data were collected using a cell analyzer. PVDF, polyvinylidene difluoride.

clones reacted with SK-BR-3 cells, which express endogenous HER2 (data not shown). Then, mAbs were further selected according to their efficacy on Western blot analysis. These analyses identified only one clone from LN229/HER2 immunizations and two clones from HER2ec immunizations that were useful for Western blot analyses, and the most sensitive clone H₂Mab-77 (IgG₁, kappa; from HER2ec immunization) was selected for subsequent studies.

Characterization of H₂Mab-77

In flow cytometric analyses, H₂Mab-77 reacted with LN229/HER2 more strongly than with endogenous HER2-expressing LN229 glioblastoma cells (Fig. 1A). H₂Mab-77 also reacted with CHO/HER2 and did not react with the parental cell strain CHO-K1, indicating that H₂Mab-77 is specific for HER2 (Fig. 1A). H₂Mab-77 also recognized endogenous HER2 in A431 epidermoid carcinoma cells, SK-BR-3 breast cancer cells, HEK-293T kidney epithelial cells, and Met-5A mesothelial cells (Fig. 1B). In subsequent Western blot analyses against LN229, LN229/HER2, and SK-BR-3 cells (Fig. 1C), H₂Mab-77 detected a 180–200 kDa protein in LN229/HER2 and SK-BR-3 cells, indicating that H₂Mab-77 is very useful for Western blot analyses. We further determined the binding affinity of H₂Mab-77 for A431 and SK-BR-3 cells using flow cytometry (Fig. 1D) and calculated K_D values for H₂Mab-77 of 2.1×10^{-9} M against A431 and 7.3×10^{-9} M against SK-BR-3, indicating that H₂Mab-77 possesses high affinity, particularly for A431 cells.

Immunohistochemical analysis against breast cancers

Finally, we investigated the immunohistochemical utility of H₂Mab-77 in human breast cancers. As shown in Figure 2A, H₂Mab-77 stained membranes of cancer cells in this patient, who was previously diagnosed with HER2-positive breast cancer using HerceptTest. In contrast, H₂Mab-77 did not stain any adjacent breast tissues (Fig. 2B).

In immunohistochemical analyses using H₂Mab-77 against two breast cancer tissue microarrays (Supplementary Table S1), H₂Mab-77 stained 13 of 58 (22.4%) invasive ductal carcinomas and one medullary carcinoma (Supplementary Table S2). Typical staining patterns are presented in Supplementary Figure S1.

Discussion

Establishment of mAbs that are useful for flow cytometry, Western blot, and immunohistochemical analyses is generally difficult. Moreover, designs of immunogens and screening methods to produce specific mAbs vary between Western blot and immunohistochemical applications, and it is very difficult to produce specific and sensitive mAbs that detect endogenous proteins. In this study, we used our original method for producing mAbs and immunized mice with LN229/HER2 or purified HER2ec from LN229/HER2ec cells. Among the 100 anti-HER2 mAbs developed herein, only three were applicable to Western blot analyses.

Among 100 clones of anti-HER2 mAbs, 97 (97%) were identified as belonging to the IgG₁ subclass, and the remaining three to the IgG_{2b} subclass. H₂Mab-77 was also determined to be of the IgG₁ subclass, precluding confirmation of antibody-dependent cellular cytotoxicity (ADCC) or




FIG. 2. Immunohistochemical analysis by H₂Mab-77 against breast cancers. Sections were incubated with 1 μ g/mL of primary H₂Mab-77 for 1 hour at room temperature followed by treatment with Envision+ kit for 30 minutes. Color was developed using 3, 3-diaminobenzidine tetrahydrochloride (DAB) for 2 minutes, and sections were then counterstained with hematoxylin. (A) Breast cancer; (B) normal breast tissues; scale bar = 100 μ m.

complement-dependent cytotoxicity (CDC) activities using H₂Mab-77. Thus, in future studies, we will convert the subclass H₂Mab-77 into mouse IgG_{2a} or IgG_{2b} subclasses or human IgG₁, and assess their applications to measure ADCC/CDC activities.^(12,17,18)

We previously produced an anti-podoplanin cancer-specific mAb (CasMab), clone LpMab-2^(9,18) or LpMab-23⁽¹⁹⁾ which specifically recognizes cancer-type podoplanin in tumor tissues. For this technology, it is critical that immunogens are produced using cancer cell lines, such as LN229 glioblastoma cells, which express cancer-specific glycan-attached membrane proteins. This technology was also useful for generating anti-glycopeptide mAbs (GpMabs), including LpMab-3,⁽²⁰⁾ LpMab-9,⁽²¹⁾ LpMab-12,⁽²²⁾ LpMab-19,⁽²³⁾ and LpMab-21.^(24,25) Furthermore, we used this technology to generate mAbs that bind to various novel epitopes of podoplanin, including LpMab-7,^(10–12) LpMab-10,⁽²⁶⁾ LpMab-13,⁽²⁷⁾ and LpMab-17.⁽²⁸⁾ We have also developed sensitive and specific anti-podocalyxin mAbs using the same methods.⁽¹³⁾ Among anti-podocalyxin mAbs, clone PcMab-47 was reportedly useful in flow cytometry, Western blot, and immunohistochemical analyses, warranting consideration of PcMab-47 in investigations of podocalyxin expression and function in cancers and normal tissues. Moreover, this method could be used to develop useful mAbs against multiple membrane proteins.

Many other studies about antibody production and antibody engineering targeting HER2 have been performed. Luo

et al. recently reported the glycoengineering of pertuzumab and its impact on the pharmacokinetic/pharmacodynamic properties.⁽²⁹⁾ They showed that fucose was critical for ADCC activity by influencing the interaction between pertuzumab and Fc γ RIIIa, and removal of sialic acid using sialidase hydrolysis increased the ADCC and CDC activity of pertuzumab. Lopez-Albaitero et al. demonstrated that a novel HER2/CD3 bispecific antibody (HER2-BsAb) recruits and activates nonspecific circulating T cells, promoting T cell tumor infiltration and ablating HER2-positive tumors, even when these are resistant to standard HER2-targeted therapies.⁽³⁰⁾ Menderes et al. reported that SYD985, a novel HER2-targeting ADC, is more potent than trastuzumab emtansine (T-DM1) against epithelial ovarian cancer.⁽³¹⁾ Sokolova et al. reported that immunotoxin 4D5scFv-PE40, which comprises 4D5scFv anti-HER2 antibody as a targeting module and fragment of *Pseudomonas* exotoxin A as an effector (toxic), showed significant antitumor effect on HER2-positive cancer cells *in vitro* and on HER2-positive xenograft models *in vivo*.⁽³²⁾ In the same way with those studies, our established H₂Mab-77 should be converted to ADC, immunotoxin, bispecific antibody with CD3, or glycoengineering mAbs to target effectively HER2-positive breast cancers.

In conclusion, from 100 mAb clones, H₂Mab-77 was highly efficacious in Western blot analyses and produced strong staining in breast cancers. Hence, the mAb H₂Mab-77 was useful in all the present experiments and will likely be a useful tool for the pathological identification of HER2 breast cancers.

Acknowledgments

We thank Yoshimi Nakamura and Yoshikazu Satoh for excellent technical assistance. This work was mainly supported by the Basic Science and Platform Technology Program for Innovative Biological Medicine from Japan Agency for Medical Research and development, AMED (Y.K.). This work was also supported, in part, by the Platform Project for Supporting Drug Discovery and Life Science Research from AMED (Y.K.), by Project for utilizing glycans in the development of innovative drug discovery technologies from AMED (Y.K.), by the Platform for Drug Discovery, Informatics, and Structural Life Science (PDIS) from AMED (Y.K.), and by JSPS KAKENHI Grant Number 17K07299 (M.K.K.) and 16K10748 (Y.K.). This work was performed, in part, under the Cooperative Research Program of Institute for Protein Research, Osaka University, CR-17-05, and by the Grant for Joint Research Project of the Institute of Medical Science, the University of Tokyo. The authors would like to thank Enago (www.enago.jp) for the English language review.

Author Disclosure Statement

Y.K. received research funding from Ono Pharmaceutical Co., Ltd.

References

- Slamon DJ, Clark GM, Wong SG, Levin WJ, Ullrich A, and McGuire WL: Human breast cancer: Correlation of relapse and survival with amplification of the HER-2/neu oncogene. *Science* 1987;235:177–182.
- Howlander N, Altekruse SF, Li CI, Chen VW, Clarke CA, Ries LA, and Cronin KA: US incidence of breast cancer subtypes defined by joint hormone receptor and HER2 status. *J Natl Cancer Inst* 2014;106:pii: dju055.
- Valabrega G, Montemurro F, and Aglietta M: Trastuzumab: Mechanism of action, resistance and future perspectives in HER2-overexpressing breast cancer. *Ann Oncol* 2007;18: 977–984.
- Amiri-Kordestani L, Wedam S, Zhang L, Tang S, Tilley A, Ibrahim A, Justice R, Pazdur R, and Cortazar P: First FDA approval of neoadjuvant therapy for breast cancer: Pertuzumab for the treatment of patients with HER2-positive breast cancer. *Clin Cancer Res* 2014;20:5359–5364.
- Tevaarwerk AJ, and Kolesar JM: Lapatinib: A small-molecule inhibitor of epidermal growth factor receptor and human epidermal growth factor receptor-2 tyrosine kinases used in the treatment of breast cancer. *Clin Ther* 2009;31 Pt 2:2332–2348.
- Lambert JM, and Chari RV: Ado-trastuzumab Emtansine (T-DM1): An antibody-drug conjugate (ADC) for HER2-positive breast cancer. *J Med Chem* 2014;57:6949–6964.
- Slamon DJ, Leyland-Jones B, Shak S, Fuchs H, Paton V, Bajamonde A, Fleming T, Eiermann W, Wolter J, Pegram M, Baselga J, and Norton L: Use of chemotherapy plus a monoclonal antibody against HER2 for metastatic breast cancer that overexpresses HER2. *N Engl J Med* 2001;344: 783–792.
- Swain SM, Kim SB, Cortes J, Ro J, Semiglazov V, Campone M, Ciruelos E, Ferrero JM, Schneeweiss A, Knott A, Clark E, Ross G, Benyunes MC, and Baselga J: Pertuzumab, trastuzumab, and docetaxel for HER2-positive metastatic breast cancer (CLEOPATRA study): Overall survival results from a randomised, double-blind, placebo-controlled, phase 3 study. *Lancet Oncol* 2013;14:461–471.
- Kato Y, and Kaneko MK: A cancer-specific monoclonal antibody recognizes the aberrantly glycosylated podoplanin. *Sci Rep* 2014;4:5924.
- Oki H, Kaneko MK, Ogasawara S, Tsujimoto Y, Liu X, Sugawara M, Takakubo Y, Takagi M, and Kato Y: Characterization of a monoclonal antibody LpMab-7 recognizing non-PLAG domain of podoplanin. *Monoclon Antib Immunodiagn Immunother* 2015;34:174–180.
- Kaneko MK, Oki H, Ogasawara S, Takagi M, and Kato Y: Anti-podoplanin monoclonal antibody LpMab-7 detects metastatic legions of osteosarcoma. *Monoclon Antib Immunodiagn Immunother* 2015;34:154–161.
- Kato Y, Kunita A, Abe S, Ogasawara S, Fujii Y, Oki H, Fukayama M, Nishioka Y, and Kaneko MK: The chimeric antibody chLpMab-7 targeting human podoplanin suppresses pulmonary metastasis via ADCC and CDC rather than via its neutralizing activity. *Oncotarget* 2015;6:36003–36018.
- Ogasawara S, Kaneko MK, Yamada S, Honma R, Nakamura T, Saidoh N, Yanaka M, Yoshida K, Fujii Y, and Kato Y: PcMab-47: Novel Antihuman Podocalyxin Monoclonal Antibody for Immunohistochemistry. *Monoclon Antib Immunodiagn Immunother* 2017;36:50–56.
- Fujii Y, Kaneko MK, and Kato Y: MAP Tag: A novel tagging system for protein purification and detection. *Monoclon Antib Immunodiagn Immunother* 2016;35: 293–299.
- Fujii Y, Kaneko M, Neyazaki M, Nogi T, Kato Y, and Takagi J: PA tag: A versatile protein tagging system using a super high affinity antibody against a dodecapeptide

- derived from human podoplanin. *Protein Expr Purif* 2014; 95:240–247.
16. Fujii Y, Kaneko MK, Ogasawara S, Yamada S, Yanaka M, Nakamura T, Saidoh N, Yoshida K, Honma R, and Kato Y: Development of RAP tag, a novel tagging system for protein detection and purification. *Monoclon Antib Immunodiagn Immunother* 2017;36:68–71.
 17. Yamada S, Kaneko MK, Nakamura T, Ichii O, Konnai S, and Kato Y: Development of mPMab-1, a mouse-rat chimeric antibody against mouse podoplanin. *Monoclon Antib Immunodiagn Immunother* 2017;36:77–79.
 18. Kaneko MK, Yamada S, Nakamura T, Abe S, Nishioka Y, Kunita A, Fukayama M, Fujii Y, Ogasawara S, and Kato Y: Antitumor activity of chLpMab-2, a human-mouse chimeric cancer-specific antihuman podoplanin antibody, via antibody-dependent cellular cytotoxicity. *Cancer Med* 2017;6:768–777.
 19. Yamada S, Ogasawara S, Kaneko MK, and Kato Y: LpMab-23: A cancer-specific monoclonal antibody against human podoplanin. *Monoclon Antib Immunodiagn Immunother* 2017;36:72–76.
 20. Oki H, Ogasawara S, Kaneko MK, Takagi M, Yamauchi M, and Kato Y: Characterization of monoclonal antibody LpMab-3 recognizing sialylated glycopeptide of podoplanin. *Monoclon Antib Immunodiagn Immunother* 2015;34:44–50.
 21. Kaneko MK, Oki H, Hozumi Y, Liu X, Ogasawara S, Takagi M, Goto K, and Kato Y: Monoclonal antibody LpMab-9 recognizes O-glycosylated N-terminus of human podoplanin. *Monoclon Antib Immunodiagn Immunother* 2015;34:310–317.
 22. Kato Y, Ogasawara S, Oki H, Goichberg P, Honma R, Fujii Y, and Kaneko MK: LpMab-12 established by CasMab technology specifically detects sialylated O-glycan on Thr52 of platelet aggregation-stimulating domain of human podoplanin. *PLoS One* 2016;11:e0152912.
 23. Ogasawara S, Kaneko MK, and Kato Y: LpMab-19 recognizes sialylated O-glycan on Thr76 of human podoplanin. *Monoclon Antib Immunodiagn Immunother* 2016;35:245–253.
 24. Kaneko MK, Nakamura T, Honma R, Ogasawara S, Fujii Y, Abe S, Takagi M, Harada H, Suzuki H, Nishioka Y, and Kato Y: Development and characterization of anti-glycopeptide monoclonal antibodies against human podoplanin, using glycan-deficient cell lines generated by CRISPR/Cas9 and TALEN. *Cancer Med* 2017;6:382–396.
 25. Kato Y, Kunita A, Fukayama M, Abe S, Nishioka Y, Uchida H, Tahara H, Yamada S, Yanaka M, Nakamura T, Saidoh N, Yoshida K, Fujii Y, Honma R, Takagi M, Ogasawara S, Murata T, and Kaneko MK: Antiglycopeptide mouse monoclonal antibody LpMab-21 exerts antitumor activity against human podoplanin through antibody-dependent cellular cytotoxicity and complement-dependent cytotoxicity. *Monoclon Antib Immunodiagn Immunother* 2017;36:20–24.
 26. Ogasawara S, Oki H, Kaneko MK, Hozumi Y, Liu X, Honma R, Fujii Y, Nakamura T, Goto K, Takagi M, and Kato Y: Development of monoclonal antibody LpMab-10 recognizing non-glycosylated PLAG1/2 domain including Thr34 of human podoplanin. *Monoclon Antib Immunodiagn Immunother* 2015;34:318–326.
 27. Ogasawara S, Kaneko MK, Honma R, Oki H, Fujii Y, Takagi M, Suzuki H, and Kato Y: Establishment of mouse monoclonal antibody LpMab-13 against human podoplanin. *Monoclon Antib Immunodiagn Immunother* 2016;35:155–162.
 28. Kato Y, Ogasawara S, Oki H, Honma R, Takagi M, Fujii Y, Nakamura T, Saidoh N, Kanno H, Umetsu M, Kamata S, Kubo H, Yamada M, Sawa Y, Morita K, Harada H, Suzuki H, and Kaneko MK: Novel monoclonal antibody LpMab-17 developed by CasMab technology distinguishes human podoplanin from monkey podoplanin. *Monoclon Antib Immunodiagn Immunother* 2016;35:109–116.
 29. Luo C, Chen S, Xu N, Wang C, Sai WB, Zhao W, Li YC, Hu XJ, Tian H, Gao XD, and Yao WB: Glycoengineering of pertuzumab and its impact on the pharmacokinetic/pharmacodynamic properties. *Sci Rep* 2017;7:46347.
 30. Lopez-Albaitero A, Xu H, Guo H, Wang L, Wu Z, Tran H, Chandralapaty S, Scaltriti M, Janjigian Y, de Stanchina E, and Cheung NV: Overcoming resistance to HER2-targeted therapy with a novel HER2/CD3 bispecific antibody. *Oncotarget* 2017;6:e1267891.
 31. Menderes G, Bonazzoli E, Bellone S, Black J, Altwerger G, Masserdotti A, Pettinella F, Zammataro L, Buza N, Hui P, Wong S, Litkouhi B, Ratner E, Silasi DA, Huang GS, Azodi M, Schwartz PE, and Santin AD: SYD985, a novel duocarmycin-based HER2-targeting antibody-drug conjugate, shows promising antitumor activity in epithelial ovarian carcinoma with HER2/Neu expression. *Gynecol Oncol* 2017;146:179–186.
 32. Sokolova E, Guryev E, Yudinsev A, Vodenev V, Deyev S, and Balalaeva I: HER2-specific recombinant immunotoxin 4D5scFv-PE40 passes through retrograde trafficking route and forces cells to enter apoptosis. *Oncotarget* 2017;8:22048–22058.

Address correspondence to:

Dr. Yukinari Kato

New Industry Creation Hatchery Center

Tohoku University

Department of Antibody Drug Development

Tohoku University Graduate School of Medicine

2-1 Seiryomachi

Aoba-ku

Sendai

Miyagi 980-8575

Japan

E-mail: yukinari-k@bea.hi-ho.ne.jp

yukinari.kato@med.tohoku.ac.jp

Received: May 11, 2017

Accepted: June 14, 2017